Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group S.p.A. delivered second-quarter results reflecting broad-based growth across its pharmaceutical and diagnostic solutions portfolio. Total company revenue expanded 8%, with the Biopharmaceutical and Diagnostic Solutions segment advancing 9%, while the Engineering division experienced a modest contraction. High-value solutions, which now comprise 45% of total revenue, posted accelerated growth of 16% year-over-year, supported by a 30% increase in biologics demand.
The company comp